Defining High Risk Prostate Cancer-Where do we Set the Bar? A Translational Science Approach to Risk Stratification

Ian M. Thompson

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Purpose: Risk stratification is commonly used in patients with prostate cancer but this effort has had no demonstrable effect on patient decision making for initial therapy. We propose new risk strata for clinically localized prostate cancer. Materials and Methods: We examined current stratification methods for prostate cancer and their impact on prostate cancer therapy. Results: Three risk strata for patients with clinically localized prostate cancer are proposed. Stratum 1 includes patients in whom active surveillance is associated with a low risk of disease progression. Stratum 2 includes patients in whom monotherapy, including external beam, interstitial radiotherapy or radical prostatectomy, is generally successful. Stratum 3 includes patients at high risk for recurrence with monotherapy in whom multimodal therapy may be superior. Conclusions: Risk stratification systems for prostate cancer should harmonize the needs of researchers to develop comparable groupings of patients, of patients who seek guidance on optimal therapy and of clinical trialists who seek to advance therapy for this disease. Our new stratification system provides such a structure.

Original languageEnglish (US)
JournalJournal of Urology
Volume176
Issue number6 SUPPL.
DOIs
StatePublished - Dec 2006

Fingerprint

Prostatic Neoplasms
Therapeutics
Brachytherapy
Prostatectomy
Disease Progression
Decision Making
Research Personnel
Recurrence

Keywords

  • prostate
  • prostate-specific antigen
  • prostatic neoplasms
  • risk

ASJC Scopus subject areas

  • Urology

Cite this

Defining High Risk Prostate Cancer-Where do we Set the Bar? A Translational Science Approach to Risk Stratification. / Thompson, Ian M.

In: Journal of Urology, Vol. 176, No. 6 SUPPL., 12.2006.

Research output: Contribution to journalArticle

@article{30d6d42295fc4ed4b09fba6a603d1b23,
title = "Defining High Risk Prostate Cancer-Where do we Set the Bar? A Translational Science Approach to Risk Stratification",
abstract = "Purpose: Risk stratification is commonly used in patients with prostate cancer but this effort has had no demonstrable effect on patient decision making for initial therapy. We propose new risk strata for clinically localized prostate cancer. Materials and Methods: We examined current stratification methods for prostate cancer and their impact on prostate cancer therapy. Results: Three risk strata for patients with clinically localized prostate cancer are proposed. Stratum 1 includes patients in whom active surveillance is associated with a low risk of disease progression. Stratum 2 includes patients in whom monotherapy, including external beam, interstitial radiotherapy or radical prostatectomy, is generally successful. Stratum 3 includes patients at high risk for recurrence with monotherapy in whom multimodal therapy may be superior. Conclusions: Risk stratification systems for prostate cancer should harmonize the needs of researchers to develop comparable groupings of patients, of patients who seek guidance on optimal therapy and of clinical trialists who seek to advance therapy for this disease. Our new stratification system provides such a structure.",
keywords = "prostate, prostate-specific antigen, prostatic neoplasms, risk",
author = "Thompson, {Ian M.}",
year = "2006",
month = "12",
doi = "10.1016/j.juro.2006.06.078",
language = "English (US)",
volume = "176",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "6 SUPPL.",

}

TY - JOUR

T1 - Defining High Risk Prostate Cancer-Where do we Set the Bar? A Translational Science Approach to Risk Stratification

AU - Thompson, Ian M.

PY - 2006/12

Y1 - 2006/12

N2 - Purpose: Risk stratification is commonly used in patients with prostate cancer but this effort has had no demonstrable effect on patient decision making for initial therapy. We propose new risk strata for clinically localized prostate cancer. Materials and Methods: We examined current stratification methods for prostate cancer and their impact on prostate cancer therapy. Results: Three risk strata for patients with clinically localized prostate cancer are proposed. Stratum 1 includes patients in whom active surveillance is associated with a low risk of disease progression. Stratum 2 includes patients in whom monotherapy, including external beam, interstitial radiotherapy or radical prostatectomy, is generally successful. Stratum 3 includes patients at high risk for recurrence with monotherapy in whom multimodal therapy may be superior. Conclusions: Risk stratification systems for prostate cancer should harmonize the needs of researchers to develop comparable groupings of patients, of patients who seek guidance on optimal therapy and of clinical trialists who seek to advance therapy for this disease. Our new stratification system provides such a structure.

AB - Purpose: Risk stratification is commonly used in patients with prostate cancer but this effort has had no demonstrable effect on patient decision making for initial therapy. We propose new risk strata for clinically localized prostate cancer. Materials and Methods: We examined current stratification methods for prostate cancer and their impact on prostate cancer therapy. Results: Three risk strata for patients with clinically localized prostate cancer are proposed. Stratum 1 includes patients in whom active surveillance is associated with a low risk of disease progression. Stratum 2 includes patients in whom monotherapy, including external beam, interstitial radiotherapy or radical prostatectomy, is generally successful. Stratum 3 includes patients at high risk for recurrence with monotherapy in whom multimodal therapy may be superior. Conclusions: Risk stratification systems for prostate cancer should harmonize the needs of researchers to develop comparable groupings of patients, of patients who seek guidance on optimal therapy and of clinical trialists who seek to advance therapy for this disease. Our new stratification system provides such a structure.

KW - prostate

KW - prostate-specific antigen

KW - prostatic neoplasms

KW - risk

UR - http://www.scopus.com/inward/record.url?scp=33750469039&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750469039&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2006.06.078

DO - 10.1016/j.juro.2006.06.078

M3 - Article

C2 - 17084160

AN - SCOPUS:33750469039

VL - 176

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 6 SUPPL.

ER -